Subtopic Deep Dive
Age-Related Clonal Hematopoiesis in CLL
Research Guide
What is Age-Related Clonal Hematopoiesis in CLL?
Age-Related Clonal Hematopoiesis in CLL refers to the coexistence of CHIP/DH mutations such as DNMT3A, TET2, and ASXL1 with chronic lymphocytic leukemia clones and their effects on therapy response and survival.
CHIP mutations occur frequently in aging CLL patients, contributing to clonal evolution and inflammation. Studies link these mutations to venetoclax resistance and cardiovascular risks (Raveché et al., 2007). Over 279 citations document NZB mouse models mimicking human CLL with microRNA-16 locus abnormalities syntenic to 13q14.
Why It Matters
CHIP in CLL patients elevates cardiovascular event risks, necessitating integrated cardio-oncology care. Venetoclax resistance tied to DNMT3A/TET2 clones impacts survival outcomes, guiding personalized therapies. Mouse models from Raveché et al. (2007, 279 citations) and Lamy et al. (2010, 282 citations) on LGL leukemia inform clonal expansion mechanisms in CLL therapy-related contexts.
Key Research Challenges
Distinguishing CHIP from CLL Clones
Separating age-related CHIP mutations from CLL driver mutations requires high-sensitivity sequencing to track clonal dominance. Misattribution affects therapy decisions (Pedersen-Bjergaard et al., 1990). Cytogenetic defects in chromosomes 5/7 complicate lineage assignment in therapy-related cases.
Quantifying Therapy Resistance Impact
DNMT3A/TET2 mutations confer venetoclax resistance, but interaction with CLL genetics remains unclear. Survival models must integrate CHIP burden (Lamy et al., 2010). Inflammation from CHIP clones accelerates progression.
Modeling Clonal Evolution Dynamics
NZB mouse models replicate CLL with miR-16/13q14 defects, but human translation lags (Raveché et al., 2007). Evolutionary trajectories of coexisting clones need longitudinal tracking. Prognostic cytogenetics from Pedersen-Bjergaard et al. (1990) highlight therapy-related evolution risks.
Essential Papers
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Thomas O’Hare, Christopher A. Eide, Michael W. Deininger · 2007 · Blood · 637 citations
Mutations in the kinase domain (KD) of BCR-ABL are the most prevalent mechanism of acquired imatinib resistance in patients with chronic myeloid leukemia (CML). Here we examine predisposing factors...
MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches
Amanda Winters, Kathrin M. Bernt · 2017 · Frontiers in Pediatrics · 400 citations
The mixed-lineage leukemia 1 (MLL1) gene (now renamed <i>Lysine [K]-specific MethylTransferase 2A</i> or <i>KMT2A</i>) on chromosome 11q23 is disrupted in a unique group of acute leukemias. More th...
Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell–derived lymphomas
David Vallois, Maria Pamela Dobay, Ryan D. Morin et al. · 2016 · Blood · 310 citations
Key Points A high frequency of diverse activating mutations in costimulatory/TCR-related signaling genes occurs in AITL and other TFH-derived PTCL. Deregulated TCR activation may play a role in the...
Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIalpha.
Michelle A. Kelliher, David C. Seldin, Philip Leder · 1996 · The EMBO Journal · 294 citations
Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia
J Pedersen-Bjergaard, P Philip, S O Larsen et al. · 1990 · Blood · 284 citations
Abstract Cytogenetic studies of 91 consecutive patients with therapy-related myelodysplasia or overt acute nonlymphocytic leukemia disclosed characteristic defects of chromosome 7 in 48 cases and o...
How I treat LGL leukemia
Thierry Lamy, Thomas P. Loughran · 2010 · Blood · 282 citations
Abstract Large granular lymphocyte (LGL) leukemia is characterized by a clonal expansion of either CD3+ cytotoxic T or CD3− NK cells. Prominent clinical features of T-LGL leukemia include neutropen...
Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice
Elizabeth Raveché, Erica Salerno, Brian J. Scaglione et al. · 2007 · Blood · 279 citations
Abstract New Zealand black (NZB) mice with autoimmune and B lymphoproliferative disease (B-LPD) are a model for human chronic lymphocytic leukemia (CLL). A genomewide linkage scan of the NZB loci a...
Reading Guide
Foundational Papers
Start with Raveché et al. (2007, 279 citations) for NZB-CLL model with miR-16/13q14 synteny; Lamy et al. (2010, 282 citations) for clonal expansion in LGL leukemia; Pedersen-Bjergaard et al. (1990, 284 citations) for cytogenetic prognostic factors.
Recent Advances
Estupiñán et al. (2021, 232 citations) on BTK inhibitors relevant to CLL therapy contexts; Winters et al. (2017, 400 citations) updates MLL-rearranged leukemia science.
Core Methods
Genomewide linkage scans (Raveché et al., 2007); cytogenetic analysis of chromosomes 5/7 (Pedersen-Bjergaard et al., 1990); clonal expansion tracking in T-LGL (Lamy et al., 2010).
How PapersFlow Helps You Research Age-Related Clonal Hematopoiesis in CLL
Discover & Search
Research Agent uses searchPapers and exaSearch to query 'CHIP DNMT3A TET2 in CLL venetoclax resistance', surfacing Raveché et al. (2007) NZB model paper; citationGraph reveals 279 backlinks to CLL progression studies; findSimilarPapers expands to Lamy et al. (2010) LGL leukemia clonal insights.
Analyze & Verify
Analysis Agent applies readPaperContent to extract mutation frequencies from Raveché et al. (2007), verifies clonal synteny claims via verifyResponse (CoVe); runPythonAnalysis computes survival correlations from extracted data using pandas; GRADE grading scores evidence strength for therapy resistance links.
Synthesize & Write
Synthesis Agent detects gaps in CHIP-CLL interaction models, flags contradictions between mouse (Raveché et al., 2007) and human cytogenetics (Pedersen-Bjergaard et al., 1990); Writing Agent uses latexEditText, latexSyncCitations for review drafts, latexCompile for figures, exportMermaid for clonal evolution diagrams.
Use Cases
"Analyze survival data from CHIP mutations in CLL patients using Python."
Research Agent → searchPapers 'CHIP CLL survival' → Analysis Agent → readPaperContent (Lamy et al., 2010) → runPythonAnalysis (pandas Kaplan-Meier plot from extracted neutropenia/anemia data) → matplotlib survival curve output.
"Draft LaTeX review on DNMT3A/TET2 in CLL therapy resistance."
Synthesis Agent → gap detection on venetoclax data → Writing Agent → latexEditText (insert Raveché et al., 2007 citations) → latexSyncCitations → latexCompile → PDF with clonal hematopoiesis figure.
"Find code for modeling clonal evolution in leukemia."
Research Agent → citationGraph (Pedersen-Bjergaard et al., 1990) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → Python scripts for chromosome aberration simulations.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'clonal hematopoiesis CLL', structures report with CHIP mutation frequencies from Raveché et al. (2007). DeepScan applies 7-step CoVe checkpoints to verify venetoclax resistance claims in Lamy et al. (2010). Theorizer generates hypotheses on CHIP-driven inflammation from NZB models.
Frequently Asked Questions
What defines Age-Related Clonal Hematopoiesis in CLL?
Coexistence of CHIP/DH mutations (DNMT3A, TET2, ASXL1) with CLL clones impacting therapy and survival.
What methods study CHIP in CLL?
High-sensitivity sequencing distinguishes CHIP from CLL clones; NZB mouse models with miR-16/13q14 synteny replicate disease (Raveché et al., 2007).
What are key papers on this subtopic?
Raveché et al. (2007, 279 citations) links miR-16 locus to CLL in NZB mice; Lamy et al. (2010, 282 citations) details clonal expansions in related leukemias; Pedersen-Bjergaard et al. (1990, 284 citations) analyzes cytogenetic aberrations.
What open problems exist?
Quantifying CHIP contribution to venetoclax resistance; longitudinal tracking of clonal evolution; translating mouse models to human prognosis.
Research Chronic Lymphocytic Leukemia Research with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Age-Related Clonal Hematopoiesis in CLL with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.